VEGFA and neoplasm: Orantinib (SU6668), a synthetic oxindole, is a potent inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptors, and has shown antiangiogenic effects and regression in human tumor xenografts [60].